38 results
SC 13E3/A
EX-99
STSA
Satsuma Pharmaceuticals Inc
8 Jun 23
Going private transaction (amended)
9:16am
in effect.
“FDA” means the U.S. Food and Drug Administration.
“Financial Expert” means an independent certified public accounting firm of nationally … to do so, Parent and the Acting Holders (on behalf of the CVR Holders) shall jointly engage the Financial Expert, whose appointment shall be final
SC 14D9/A
STSA
Satsuma Pharmaceuticals Inc
30 May 23
Tender offer solicitation (amended)
9:42pm
be consummated, an injunction directing the Company Board to comply with the Act, and an award of attorney’s and expert fees and expenses. Purchaser and Parent … with the Act, and an award of attorney’s and expert fees and expenses. Purchaser and Parent are not named as parties to the lawsuits. The above
SC 14D9
STSA
Satsuma Pharmaceuticals Inc
5 May 23
Tender offer solicitation
8:17am
with no further clinical trials (based on interactions with the FDA and input from its expert regulatory consultants), (ii) the commercial potential
8-K
EX-10.1
73o8 ujbg7hl23g7yx7
17 Apr 23
SNBL to Acquire Satsuma Pharmaceuticals
6:34am
SC TO-C
EX-99.2
l3beeg3 bs5
17 Apr 23
Information about tender offer
6:08am
8-K
EX-99.1
sb8xcg avl8lanezuv
20 Dec 22
Satsuma Pharmaceuticals Provides STS101 Development Program and Corporate Update
4:19pm
8-K
EX-99.2
zld7xmkb38vwe5hpc4k
20 Dec 22
Satsuma Pharmaceuticals Provides STS101 Development Program and Corporate Update
4:19pm
8-K
EX-99.1
er12lfgb8ufrjquw o4s
30 Nov 22
Other Events
4:00pm
8-K
EX-99.2
92st5mxa fdjrxz
1 Mar 21
Satsuma Pharmaceuticals Announces Updated STS101 Development Plan
12:00am